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However, we did not compare the incidence of active B. burgdor-
feri infections in dogs and people, but, rather, the prevalence of
antibody in these two species. We found that the seropositivity
rate (an index of exposure), was greater in dogs than in people
in this population.
ThOMAS R. ENG
Viral and Rickettsial Zoonoses Branch, Centers for Disease
Control, Atlanta, Georgia
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Interpretation of Data Regarding the Protection
Afforded by Serum, IgG, or IgM Antibodies after
Immunization with the Rough Mutant R595
of Salmonella minnesota
To THE EDITOR - Several crucial problems in the field of protec-
tive antibody to endotoxin core were summarized by Ziegler in
an editorial in the August 1988 issue [lJ. One is the controversy
regarding the protection observed with core antibodies in ex-
perimental animals; some investigators who have been unable to
reproduce the results published by others have raised the issue
of proper controls [2, 3J. Another important problem is that the
epitope specificity and the immunoglobulin class of the core an-
tibodies responsible for protection are debated. Two papers in
the same issue addressed these problems experimentally [4, 5J.
McCabe et al. [4J fractionated sera of both rabbits and hu-
mans immunized with the Re mutant of Salmonella minnesota
on Sephadex G200 columns (Pharmacia LKB Biotechnology, Pis-
cataway, NJ), which divide the serum proteins into three frac-
tions. They found that the first fraction, which contains IgM and
many other proteins, afforded a degree of protection similar to
that of unfractionated serum in animals challenged with two gram-
negative bacteria (Klebsiella pneumoniae and Morganella mor-
gan;') or with Salmonella typhi lipopolysaccharide (LPS). They
concluded that protection in postimmune rabbit or human sera
was mediated by IgM antibody to core LPS. Wefear that no defini-
tive proof was provided for this conclusion. First, the inference
that IgM was the protective factor is not supported by the data,
because no IgM purification was attempted. Second, the conclu-
sion that core LPS antibodies were the protective factor is also
not supported by the data, since neither irnmunopurification of
core LPS antibodies nor absorption experiments were reported.
DeMaria et al. [5] immunized 122 healthy subjects with the
rough mutant Re of S. minnesota and tested the protective power
of pre- and postimmunization sera in mice challenged with one
inoculum of the K. pneumoniae or M. morganii strains or with
one dose of S. typhi LPS. They concluded that an enhanced pro-
tective activity was demonstrated after immunization in most sub-
jects. Webelieve that this strong conclusion is not fully supported
by the data. First, the results obtained in more than half of the
volunteers immunized with the rough mutant were not reported.
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The criteria for excluding them was that their preimmune sera
were already "protective." Although the term "protection" was
not defined, one may wonder whether these exclusions were made
"a posteriori," since the reason given for exclusion was that a preex-
isting protection precluded the demonstration of any additional
protection after immunization. If "protection" is defined as hav-
ing high survival rate, excluding the volunteers with protective
preimmune sera would reduce the data to only those with low
survivals in the preimmune sera.
If one supposes that immunization does not enhance the pro-
tective activity at all, the sampling distribution of survivals for
the entire population would be the same for both pre- and postim-
mune sera. With the design of excluding protective preimmune
sera, the sampling distribution of survivals in preimmune sera
is artifically skewed toward low values, whereas the sampling dis-
tribution remains unskewed for postimmune sera. In other words,
the results are biased toward showing increased survival rates for
postimmune sera, which might lead to significant statistical differ-
ences even if the populations of pre- and postimmune sera were
actually similar. Therefore, the exclusion of the results observed
with the sera of more than half of the preimmune volunteers
represents a crucial problem. Moreover, in experiments in which
the survival of 8-10 mice injected with preimmune sera is com-
pared with the survival of a similar small number of mice injected
with postimmune sera, the experimental variability could account
for important differences in terms of observed percentage sur-
vivals. Thus, the authors' conclusions cannot be accepted unless
they report the sampling distribution of the entire population of
preimmune sera and the experimental variability in their model.
Although the studies by McCabe et al. [4J and by DeMaria
et al. [5J represent an enormous amount of work, we do not be-
lieve that the data reported support in a definitive way the con-
clusions drawn.
J. D. BAUMGARTNER, M. M. Wu, AND M. P. GLAUSER
Division of Infectious Diseases, Centre Hospitalier
Universitaire Vaudois. Lausanne. Switzerland
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Reply
To THE EDIIOR- The letter by Baumgartner et aI. [I] challenges
the findings and conclusions in our articles in the August 1988
issue [2, 3].
Although they do not challenge development of enhanced re-
sistance after immunization, they question whether the protec-
tive activity of lapine and human post-Re immunization antisera
was clearly established as due to Re IgM antibody. Also, Sepha-
dex G-200 immunoglobulin fractionation is criticized because the
fraction I (IgM) contains "many other proteins"; however, these
putative contaminants of our preparation are not identified.
Sephadex G-200 immunoglobulin fractionation is a standard
technique [4]. Although other methods may afford more com-
plete purification, Sephadex G-200 is particularly useful for IgM
isolation because it excludes proteins ~700,OOO-800,000M, [5].
Few other serum proteins are this large (only Uz macroglobulin
immediately comes to mind). It would have been helpful had
Baumgartner et aI. [I] identified the alleged contaminating pro-
teins, other than immunoglobulin, that are induced by immuniza-
tion with rough (R) but not smooth gram-negative bacilli, persist
for weeks, and clearly protect against challenge with heterolo-
gous gram-negative bacilli.
The suggestion that absorption experiments would support an-
tibody as the protective modality indicates unawareness that these
are described in two previous publications [6, 7]. Also, protec-
tive activity of whole Re and J5 antisera and their IgM fractions
is completely removed by absorption on Re and J5 lipopolysac-
charide-Sepharose columns. More recent studies (unpublished
data) of a component vaccine of modified Re or J5 LPS coupled
to a protein "carrier" (converting a T-independent to aT-dependent
antigen) demonstrated protection in the IgM fraction after pri-
mary immunization, but that "booster" immunization induced
protective activity localized almost exclusively to IgG. These studies
with component vaccines further confirm the validity of our con-
clusions.
Regarding the comments in paragraph 3, "They concluded that
an enhanced protective activity was demonstrated after immuni-
zation in most subjects" and "this strong conclusion is not fully
supported by the data," we believe that Baumgartner et aI. [I]
misinterpreted our statements. We concluded that postimmuni-
zation protection was demonstrated in almost all whose preim-
munization sera werenot protective (see pp. 303, 307, and 308 [2]).
The postulation in paragraph 3 is not clear. If it is implied that
those with protective preimmunization serum samples should be
classified as vaccine failures, this is an erroneous assumption.
These represent volunteers with preexisting high titers of specific
protective antibody to the test strains, which precluded testing
with these strains. Exclusion does not indicate that development
of protective activity would not be demonstrable if other assay
strains were available. This was illustrated in numerous subjects
with preexisting protection against one assay strain but in whom
postimmunization protection was demonstrated against the other
test strains. Ideally, we would have preferred to screen all volun-
teers initially and select only those with nonprotective sera for
immunization, but this adversely affected volunteer recruitment.
To obtain adequate numbers of volunteers, all healthy subjects
were accepted for immunization. We have previously demonstrated
that type-specific antibody exerts much greater protective activ-
ity than the lesser but significant protection afforded by antibody
to R mutants [6] as to mask protection induced by the latter. There-
fore, an a priori decision was made to assay postimmunization
protection only in those whose preimmunization sera were not
protective. Because there would be no justification for attempt-
ing to demonstrate development of protective activity in subjects
in whom such activity is present preimmunization, those with
preexisting protective activity were used only to assess vaccine
toxicity and antibody response.
Finally, the questions concerning the meaning and significance
of protective activity are best illustrated by review of tables 2,
4, and 5 [2]. We hope this information clarifies our work. We
believe the available data clearly support the conclusions expressed
in these publications.
WILLIAM R. MCCABE, ALFRED DEMARIA, JR.,
MARGARET A. JOHNS, HILDA BERBERICH
Maxwell Finland Laboratory for Infectious Diseases,
Boston City Hospital, Boston, Massachuselts
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